"uuid:ID","studyVersion","studyRationale","studyTitle","studyAcronym","id"
"e5dddfbd-5607-4bdd-b78e-d8ba613d65a7","2","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimer's Disease","H2Q-MC-LZZT","StudyVersion_1"
